Nefecon and Ambrisentan in IgA Nephropathy

PHASE4RecruitingINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
IgA NephropathyChronic Kidney DiseaseProteinuria
Interventions
DRUG

"Nefecon®,Ambrisentan"

"Subjects who meet the screening criteria will be treated with Budesonide in combination with Ambrisentan.~Budesonide (Nefecon®), 16mg/d for 36 weeks, taken orally. Ambrisentan , 5mg/d for 36 weeks, taken orally."

Trial Locations (1)

130021

RECRUITING

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER

NCT07030894 - Nefecon and Ambrisentan in IgA Nephropathy | Biotech Hunter | Biotech Hunter